Case study: Experimental lecanemab treatment causes adverse outcomes in 65-year-old woman with Alzheimer's disease

In a noteworthy case study published in the Journal of Alzheimer's Disease investigators report autopsy findings in a 65-year-old woman with Alzheimer's disease (AD) who received three open label infusions of the experimental anti-amyloid beta (Aβ) antibody drug lecanemab.

Related Keywords

Northwestern University ,Illinois ,United States ,Chicago ,Marsel Mesulam ,George Perry ,Ruth Dunbar Davee ,Rudolphj Castellani ,Pouya Jamshidi ,Lily Ramsey ,Department Of Pathology ,Semmes Distinguished University ,Department Of Neurology ,University Of Texas At San Antonio ,Feinberg School Of Medicine ,Northwestern University Feinberg School Of Medicine ,Mesulam Center ,Lead Investigator ,Northwestern University Feinberg School ,Ruth Dunbar Davee Professor ,Behavioral Neurology ,Feinberg School ,Cognitive Neurology ,Semmes Distinguished University Chair ,Alzheimer 39s Disease ,Ntibody ,Flood ,Blood Vessels ,Rain ,Maging ,Immunohistochemistry ,Intracerebral Hemorrhage ,Medicine ,Necrosis ,Eurology ,Pathology ,Phagocytosis ,Research ,Stroke ,Vasculature ,Vasculitis ,